Lucas R Watterson1, Peter R Kufahl1, Sara B Taylor1,2, Natali E Nemirovsky1, M Foster Olive1,3. 1. Arizona State University, Department of Psychology, Tempe, AZ, USA. 2. Hendrix College, Department of Psychology, Conway, AR, USA. 3. Arizona State University, Interdisciplinary Graduate Program in Neuroscience, Tempe, AZ, USA.
Abstract
BACKGROUND: In recent years, there has been a dramatic increase in abuse of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV), often in combination with other illicit stimulants. PURPOSE: We sought to determine if repeated exposure to MDPV would produce sensitization to the motor stimulant effects of the drug, and whether cross-sensitization would develop with the stimulant effects of methamphetamine (METH). STUDY DESIGN: Male Sprague-Dawley rats were administered MDPV (1 or 5 mg/kg) or saline once daily for 5 days at 24 hour intervals, or were administered MDPV (1 mg/kg) or saline once daily for 5 days at 48 hour intervals. For cross-sensitization experiments, rats were administered METH (1 mg/kg) or MDPV (1 or 5 mg/kg) once daily for 5 days at 48 hour intervals, and following a 5 day incubation period, were given an acute challenge injection of either MDPV (0.5 mg/kg) or METH (0.5 mg/kg), respectively. RESULTS: Rats repeatedly administered MDPV (1 mg/kg) every 48 hours, but not every 24 hours, demonstrated increased motor activity when given either a subsequent challenge of MDPV (0.5 mg/kg i.p.) or METH (0.5 mg/kg), indicating the development of behavioral sensitization and cross-sensitization, respectively. Moreover, rats repeatedly administered METH (1 mg/kg) every 48 hours did not exhibit cross-sensitization to the motor stimulating effects of a subsequent challenge with MDPV (0.5 mg/kg). CONCLUSION: These results suggest that specific patterns of MDPV administration may lead to lasting changes in behavioral responses to subsequent METH exposure.
BACKGROUND: In recent years, there has been a dramatic increase in abuse of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV), often in combination with other illicit stimulants. PURPOSE: We sought to determine if repeated exposure to MDPV would produce sensitization to the motor stimulant effects of the drug, and whether cross-sensitization would develop with the stimulant effects of methamphetamine (METH). STUDY DESIGN: Male Sprague-Dawley rats were administered MDPV (1 or 5 mg/kg) or saline once daily for 5 days at 24 hour intervals, or were administered MDPV (1 mg/kg) or saline once daily for 5 days at 48 hour intervals. For cross-sensitization experiments, rats were administered METH (1 mg/kg) or MDPV (1 or 5 mg/kg) once daily for 5 days at 48 hour intervals, and following a 5 day incubation period, were given an acute challenge injection of either MDPV (0.5 mg/kg) or METH (0.5 mg/kg), respectively. RESULTS:Rats repeatedly administered MDPV (1 mg/kg) every 48 hours, but not every 24 hours, demonstrated increased motor activity when given either a subsequent challenge of MDPV (0.5 mg/kg i.p.) or METH (0.5 mg/kg), indicating the development of behavioral sensitization and cross-sensitization, respectively. Moreover, rats repeatedly administered METH (1 mg/kg) every 48 hours did not exhibit cross-sensitization to the motor stimulating effects of a subsequent challenge with MDPV (0.5 mg/kg). CONCLUSION: These results suggest that specific patterns of MDPV administration may lead to lasting changes in behavioral responses to subsequent METH exposure.
Authors: Edward A Ross; Gary M Reisfield; Mary C Watson; Chris W Chronister; Bruce A Goldberger Journal: Am J Med Date: 2012-06-09 Impact factor: 4.965
Authors: L D Simmler; T A Buser; M Donzelli; Y Schramm; L-H Dieu; J Huwyler; S Chaboz; M C Hoener; M E Liechti Journal: Br J Pharmacol Date: 2013-01 Impact factor: 8.739
Authors: Lucas R Watterson; Peter R Kufahl; Natali E Nemirovsky; Kaveish Sewalia; Megan Grabenauer; Brian F Thomas; Julie A Marusich; Scott Wegner; M Foster Olive Journal: Addict Biol Date: 2012-07-11 Impact factor: 4.280
Authors: Blake A Froberg; Michael Levine; Michael C Beuhler; Bryan S Judge; Philip W Moore; Kristin M Engebretsen; Nathanael J Mckeown; Christopher D Rosenbaum; Amy C Young; Daniel E Rusyniak Journal: J Med Toxicol Date: 2015-06
Authors: John F Wyman; Eric S Lavins; David Engelhart; Erica J Armstrong; Kimberly D Snell; Paul D Boggs; Shaena M Taylor; Rindi N Norris; Frank P Miller Journal: J Anal Toxicol Date: 2013-02-13 Impact factor: 3.367
Authors: R López-Arnau; M A Luján; L Duart-Castells; D Pubill; J Camarasa; O Valverde; E Escubedo Journal: Br J Pharmacol Date: 2017-04-06 Impact factor: 8.739
Authors: Michael D Hambuchen; Howard P Hendrickson; Melinda G Gunnell; Samantha J McClenahan; Laura E Ewing; Dillon M Gibson; Michael D Berquist; S Michael Owens Journal: Drug Alcohol Depend Date: 2017-08-08 Impact factor: 4.492
Authors: Steven J Simmons; Ryan A Gregg; Fionya H Tran; Lili Mo; Eva von Weltin; David J Barker; Taylor A Gentile; Lucas R Watterson; Scott M Rawls; John W Muschamp Journal: Addict Biol Date: 2016-12-01 Impact factor: 4.280
Authors: Steven J Simmons; Jonna M Leyrer-Jackson; Chicora F Oliver; Callum Hicks; John W Muschamp; Scott M Rawls; M Foster Olive Journal: ACS Chem Neurosci Date: 2018-05-11 Impact factor: 4.418
Authors: Samantha J McClenahan; Melinda G Gunnell; S Michael Owens; William E Fantegrossi Journal: Psychopharmacology (Berl) Date: 2020-06-04 Impact factor: 4.530